BioLineRX Ltd. (IL:BLRX)
TASE:BLRX
Want to see IL:BLRX full AI Analyst Report?
BLRX Stock Chart & Stats
1.50
>-0.01(-6.00%)
At close: 4:00 PM EST
1.50
>-0.01(-6.00%)
Day’s Range― - ―
52-Week Range1.10 - 3.10
Previous CloseN/A
Volume20.50M
Average Volume (3M)4.64M
Market Cap
₪39.31M
Enterprise Value21.46M
Total Cash (Recent Filing)₪17.35M
Total Debt (Recent Filing)₪9.07M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Aug 13, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,620,977,300
10 Day Avg. Volume5,813,402
30 Day Avg. Volume4,637,561
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.68
Price to Sales (P/S)9.69
P/FCF Ratio-1.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)₪1.72M
Bulls Say, Bears Say
Bulls Say
Royalty Revenue Growth (APHEXDA)Growing APHEXDA sales generating recurring royalty income validates third‑party commercialization and creates a non‑dilutive revenue stream. Consistent royalty receipts diversify funding beyond milestones, provide durable partial funding for operations, and increase optionality for partnering or reinvestment over the next several quarters.
GLIX1 Advanced To First‑in‑humanTransitioning GLIX1 into first‑in‑human trials materially reduces preclinical risk and creates multi‑period clinical milestones. Human dosing, planned H2 2026 updates and 2027 dose‑escalation readouts provide durable clinical catalysts, strengthen IP defensibility and improve prospects for partnerships or later‑stage financing.
Manageable Leverage & Positive EquityA moderate debt load with positive equity and tangible assets gives BioLineRx balance sheet flexibility uncommon for early clinical biotechs. Manageable leverage reduces near‑term refinancing pressure versus high‑debt peers, supporting continued R&D investment and lowering structural insolvency risk over the next 2–6 months.
Bears Say
Negative Operating And Free Cash FlowSustained negative operating and free cash flow means the business cannot self‑fund development, forcing reliance on external financing or partner payments. Over months this increases dilution risk, constrains strategic choices, and could delay programs if capital markets or partner payments are unavailable.
Limited Near‑term Cash RunwayA roughly one‑year runway compels near‑term fundraising or partnering, which can pressure deal economics and execution timelines. The need to secure capital within ~12 months elevates the chance of program reprioritization, slower enrollment or dilution, making operational plans dependent on successful financing.
R&D Spend Up And PDAC Competitive UncertaintyHigher R&D (GLIX1-driven) increases cash burn while third‑party PDAC data could alter the competitive positioning of motixafortide. Together these raise execution risk: greater spending needs plus potential market shifts may force strategic changes, impacting timelines, trial design or partnering prospects.
Bioline Rx News
BLRX FAQ
What was BioLineRX Ltd.’s price range in the past 12 months?
BioLineRX Ltd. lowest stock price was 1.10 and its highest was 3.10 in the past 12 months.
What is BioLineRX Ltd.’s market cap?
BioLineRX Ltd.’s market cap is ₪39.31M.
When is BioLineRX Ltd.’s upcoming earnings report date?
BioLineRX Ltd.’s upcoming earnings report date is Aug 13, 2026 which is in 61 days.
How were BioLineRX Ltd.’s earnings last quarter?
BioLineRX Ltd. released its earnings results on May 27, 2026. The company reported 0 earnings per share for the quarter, beating the consensus estimate of -0.586 by 0.586.
Is BioLineRX Ltd. overvalued?
According to Wall Street analysts BioLineRX Ltd.’s price is currently Overvalued.
Does BioLineRX Ltd. pay dividends?
BioLineRX Ltd. does not currently pay dividends.
What is BioLineRX Ltd.’s EPS estimate?
BioLineRX Ltd.’s EPS estimate is 0.
How many shares outstanding does BioLineRX Ltd. have?
BioLineRX Ltd. has 2,620,977,300 shares outstanding.
What happened to BioLineRX Ltd.’s price movement after its last earnings report?
BioLineRX Ltd. reported an EPS of 0 in its last earnings report, beating expectations of -0.586. Following the earnings report the stock price went up 7.143%.
Which hedge fund is a major shareholder of BioLineRX Ltd.?
Currently, no hedge funds are holding shares in IL:BLRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioLineRX Ltd.
BioLineRx Ltd., an Israeli biopharmaceutical company founded in 2003 and headquartered in Hevel Modi'in, focuses its clinical development entirely on oncology. A pivotal asset in its pipeline is Motixafortide, a peptide that has successfully concluded Phase 3 clinical trials for autologous stem cell mobilization and Phase 2a trials for pancreatic cancer. This compound is also advancing through Phase 2 for metastatic pancreatic adenocarcinoma, and Phase 1b studies for acute respiratory distress syndrome stemming from COVID-19 and other viral infections, alongside ongoing investigations for solid tumors and acute myeloid leukemia. Another promising candidate, AGI-134, an immuno-oncology agent, is currently undergoing Phase 1/2a clinical trials for various solid tumors. Furthermore, BioLineRx offers BL-5010, a proprietary pen-like applicator designed for the non-surgical removal of skin lesions. The company maintains strategic collaborations, including an agreement with MSD in the cancer immunotherapy domain, a partnership with MD Anderson Cancer Center to explore Motixafortide in combination with KEYTRUDA (pembrolizumab) for pancreatic cancer, and a licensing arrangement with Perrigo Company plc for the over-the-counter sale of BL-5010.